Morgan Keegan Lowers Price Target On National Health Investors To $49
According to Morgan Keegan, National Health Investors (NYSE: NHI) price target is lowered to $49.
Morgan Keegan said that it bases its Outperform rating on National Health Investors on a view that the company has a strong portfolio and can use its underlevered balance sheet to make accretive new investments. “We are tweaking our earnings estimates, changing our 2011 FFO/FAD from $2.89/$2.83 to $2.85/$2.84 and our 2012 estimates from $3.05/$3.04 to $3.02/$3.00.”
National Health Investors closed yesterday at $40.78.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.